T-2307 is an antibiotic commonly used against Candida, exhibiting broad-spectrum antifungal activity against most pathogenic fungi in vitro and in vivo. It selectively induces collapse of yeast mitochondrial membrane potential and can be used for invasive fungal infections.

Method:
Cell viability assay was used to evaluate the inhibitory effect of T-2307 on Candida glabrata (strain ATCC 90030). The cells were exposed to various concentrations of T-2307 (0.000125, 0.00025, 0.0005, 0.001, 0.002, 0.0039, 0.0078, 0.0156, 0.0313, 0.0625, and 0.125 μg/mL) and incubated for 24 and 48 hours.

Result:
At concentrations ranging from 0.0039 to 0.125 μg/mL, C. glabrata exhibited significant trailing growth after 48 hours of incubation. Similar trailing growth was observed at 24 hours, suggesting that the inhibitory effect of T-2307 on C. glabrata is both sustained and concentration-dependent. [2]

Method:
Systemic infection models of Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus were established in 4-week-old SPF-grade male ICR mice. T-2307 was administered subcutaneously at doses of 0.001, 0.1, and 1 mg/kg once daily for 7 consecutive days, starting 2 hours after infection.

Result:
T-2307 significantly prolonged the survival of mice in all three systemic fungal infection models, showing a clear dose-dependent protective effect. The calculated ED₅₀ values were 0.00755 mg/kg for C. albicans, 0.117 mg/kg for C. neoformans, and 0.391 mg/kg for A. fumigatus. [1]